There are currently 4 active clinical trials seeking participants for Resistant Hypertension research studies. The states with the highest number of trials for Resistant Hypertension participants are Florida, California, Texas and Ontario.
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
NCT06829537
Recruiting
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Site 379, Redondo Beach, California +2 locations
Conditions: Resistant Hypertension, Hypercortisolism
Register for Updates
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
NCT06526858
Recruiting
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
03/25/2025
Locations: University of Arizona Department of Urology, Tucson, Arizona +4 locations
Conditions: Resistant Hypertension
Register for Updates
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
NCT06168409
Recruiting
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/17/2025
Locations: Research Site, Surprise, Arizona +120 locations
Conditions: Resistant Hypertension
Register for Updates
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
NCT05888233
Recruiting
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality o... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/11/2024
Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
Conditions: Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Register for Updates